Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Primary central nervous system lymphoma with initial spinal cord involvement (PCNSL-SC) is a rare entity: 4 case reports and review of literature.
Harlay V, Campello C, Bequet C, Petrirena G, Barrie M, Appay R, Arnoux I, Loosveld M, Testud B, Bertucci A, Tabouret E, Chinot O. Harlay V, et al. Among authors: bertucci a. Rev Neurol (Paris). 2024 Mar;180(3):224-229. doi: 10.1016/j.neurol.2023.10.003. Epub 2023 Oct 26. Rev Neurol (Paris). 2024. PMID: 39300797 Review. No abstract available.
GD3 ganglioside is a promising therapeutic target for glioma patients.
Hein V, Baeza-Kallee N, Bertucci A, Colin C, Tchoghandjian A, Figarella-Branger D, Tabouret E. Hein V, et al. Among authors: bertucci a. Neurooncol Adv. 2024 Mar 19;6(1):vdae038. doi: 10.1093/noajnl/vdae038. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38590763 Free PMC article. Review.
A French Multicenter Real-Life Study on the Biological and Clinical Parameters Associated With Response to Immune Checkpoint Inhibitors (ICIs) in Second-Line Treatment of Advanced Urothelial Carcinoma: Impact of Antibiotics Administration at the Time of ICIs Initiation.
Grassi P, Hilgers W, Boissier R, Bertucci A, Bruyat D, Duffaud F, Enoch F, Rochigneux P, Mancini J, Deville JL. Grassi P, et al. Among authors: bertucci a. Clin Genitourin Cancer. 2024 Dec 3;23(1):102283. doi: 10.1016/j.clgc.2024.102283. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39719789
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
Bello Roufai D, Gonçalves A, De La Motte Rouge T, Akla S, Blonz C, Grenier J, Gligorov J, Saghatchian M, Bailleux C, Simon H, Desmoulins I, Tharin Z, Renaud E, Bertho M, Benderra MA, Delaloge S, Robert L, Cottu P, Pierga JY, Loirat D, Bertucci A, Renouf B, Bidard FC, Lerebours F. Bello Roufai D, et al. Among authors: bertucci a. Oncogene. 2023 Jun;42(23):1951-1956. doi: 10.1038/s41388-022-02585-3. Epub 2023 Jan 7. Oncogene. 2023. PMID: 36611120
Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
Bello Roufai D, Gonçalves A, De La Motte Rouge T, Akla S, Blonz C, Grenier J, Gligorov J, Saghatchian M, Bailleux C, Simon H, Desmoulins I, Tharin Z, Renaud E, Bertho M, Benderra MA, Delaloge S, Robert L, Cottu P, Pierga JY, Loirat D, Bertucci A, Renouf B, Bidard FC, Lerebours F. Bello Roufai D, et al. Among authors: bertucci a. Oncogene. 2023 Apr;42(17):1417. doi: 10.1038/s41388-023-02615-8. Oncogene. 2023. PMID: 36922682 No abstract available.
103 results